Tharimmune, Inc.
A biotechnology company developing potential treatments for rare, inflammatory and oncological diseases. The company is currently working on a clinical trial of a treatment to control the symptoms of chronic, debilitating pruritus in primary biliary cholangitis (PBC) and is developing a pipeline targeting multiple solid tumors. The company is based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | New Jersey |
Employees | 2 |
Founded | 2017 |
Financials | |
|---|---|
Market Capitalization | 3.01M |
Revenue | |
Operating Income | -9.09M |
Operating Margin | |
Net Income | -8.89M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 3565 / 5373 |
Sector : Healthcare | 331 / 1144 |
Industry : Biotechnology | 90 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 5498 / 5565 |
Sector : Healthcare | 1139 / 1182 |
Industry : Biotechnology | 646 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 3420 / 5436 |
Sector : Healthcare | 328 / 1164 |
Industry : Biotechnology | 103 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 5253 / 5330 |
Sector : Healthcare | 1158 / 1174 |
Industry : Biotechnology | 654 / 667 |